PAO as a tracer, in thirty Parkinsonian patients with (n = 15) or without (n = 15) dementia, nineteen patients with dementia of the Alzheimer type (DAT) and thirteen control subjects. HM-PAO uptake was measured in the frontal, parietal, temporal and occipital cortex and tracer perfusion was expressed as corticallcerebellar activity ratios. Regional HM-PAO ratios in nondemented Parkinsonian patients did not differ from controls, whereas in demented patients with Parkinson's disease (DPD) a significant reduction was found in the parietal, temporal and occipital cortex. Tracer uptake ratios were significantly reduced in all regions in the DAT group. Thus DPD and DAT shared a common pattern of marked posterior hypoperfusion, although the perfusion defect was greater and more extensive in the DAT patients.
Intellectual deterioration occurs in 10-40% of patients with Parkinson's disease (PD),' especially in the delaved onset and akineticrigid forms of the disease. However, the nature of this dementing process and particularly its relationship with dementia of the Alzheimer type (DAT) remain controversial. 34 Measurement of regional cerebral blood flow (rCBF) using positron emission tomography (PET) or single photon emission computed tomography (SPECT) techniques provide a useful approach to the studv of human degenerative dementias.5 Whereas there is general agreement that a global reduction in rCBF and metabolism, predominantlv affecting the parieto-temporal regions is encountered in DAT,"' the available data in PD are conflicting, and do not allow distinctions in specific patterns of rCBF or metabolism between Parkinsonian patients with or without dementia.`' 13 These results led us to further investigate regional cerebral perfusion modifications in PD with or without dementia, and to compare the observed modifications to those found in patients suffering from DAT. In this study, regional cerebral perfusion was measured by SPECT using technetium-99m d,l-hexamethyl-propyleneamine oxime (9`mTc-HM.-PAO) as tracer. 4 Patients and methods
PATIENTS AND CONTROLS
Forty nine right handed patients, thirty with idiopathic PD and nineteen with probable DAT, according to the criteria of iMcKhann et al,' participated in the study (table 1) . General exclusion criteria were the following: hvpertension, cardiovascular disease, diabetes, Hachinski ischaemic score" equal to or above four, history of alcohol abuse, head trauma, serious physical illness that could affect the CNS function or a historv of other psvchiatric illness, and focal abnormalities on EEG or CT-scan. Patients with Parkinsonism that was postencephalitic, drug-induced or a feature of multisystem disease, as well as with thalamotomies, were excluded. None of the patients was taking medication known to affect overall brain metabolism or cerebral circulation, except for levodopa' or dopamine (DA) agonists. ' Experiments were carried out under resting conditions in a quiet room with reduced lighting and background noise to eliminate external acoustic and visual stimulation which are known to affect rCBF and brain metabolism.22
Patients lay supine, but awake with their eyes covered, for at least 20 minutes before injection of the radiotracer. The HM-PAO freeze-dried kit (Ceretec, Amersham International, London, UK) was reconstituted with (99mTc)-pertechnetate solution, and a dose of 925 MBq (25 mCi) was injected within 20 minutes of tracer preparation through an indwelling cannula into an antecubital vein. Computed imaging was carried out between 15-45 minutes after the injection using a single-head rotating gamma camera (Gamma-Tome Sopha Medical) coupled to a brain SPECT designed collimator (THR-BE) and a dedicated computer system (Sopha Medical S 4000). Data acquisition was performed in a sagittal plane (from 0 to 1800) from nose to occiput. For each subject, 32 angular views, each collected over 50 seconds, were recorded into a 64 x 64 matrix. Slices were then reconstructed from the prefiltered raw data (pseudo-Wiener), by the filtered backprojection algorithm using a ramp filter. No correction for attenuation was made. Reconstructed brain slices were then reorientated on the orbitomeatal line and a set of 12 axial, sagittal and coronal sections at 6 mm increments was finally obtained for each subject.
Regional tracer uptake was measured by a semi-quantitative method9 with minor modifications. For each subject, three adjacent axial slices (4 pixel thick = 24 mm) were considered: one corresponding to the cerebellum and two supratentorial (superior and inferior). On each slice, regions of interest (ROIs: 3 x 3 pixels, 18 x 18 mm), were drawn as symmetrically as possible on the cerebellar hemispheres (two pairs) and on the cortical ribbon at the following levels ( fig 1) : superior frontal (three pairs) and parietal (four pairs) for the superior supratentorial slice, inferior frontal (three pairs), temporal (four pairs) and occipital (one pair) for the inferior supratentorial one. Cerebral regions were defined according to a standard CT scan brain atlas.23 However, the limited anatomical precision inherent in this method should be borne in mind. ROIs were analysed by one investigator who was unaware of the clinical findings, and had no contact with the patients. For each right-left cortical region, as well as for the whole cerebellum, the radioactivity count densities of corresponding ROIs were averaged. Relative cortical regional perfusion was expressed as the ratio of cortical/ cerebellar activities. In this study, a semiquantitative assessment of regional cerebral perfusion comparing cortical to cerebellar ROIs was used. At present, quantitative data cannot be retrieved from SPECT. This method has been used to analyse changes in rCBF in DAT924 and PD,'0 and relies on the assumption that cerebellar rCBF is unaffected in these conditions, which is borne out by pathological25 26 duration of dementia, levodopa dosage and treatment duration, MMS score) and for cortical/cerebellar ratios of HM-PAO uptake were made by one-way analysis of variance. When significant (p < 0 05), these were followed by Scheffe's test for multiple comparisons, or by unpaired Student's t tests as appropriate. For categorical data, the Chi square test was used. Right-left regional ratio asymmetries, calculated as a right minus left/right plus left activity ratio, were evaluated in each group by a one sample Student's t test. Relationships between clinical parameters and changes in regional ratios were assessed by calculating the Spearman linear coefficient of correlation r (significance was accepted for p < 0-05). Table 2 shows the mean (SD) values of the cortical/cerebellar activity ratios obtained from the different brain regions of control subjects and patients. Although right to left asymmetries in cortical regions were occasionally observed in individual cases, overall regional mean cortical values were not significantly different on the two sides in all the groups studied (Student's t test, p > 0-05). Controls showed a homogeneous distribution of the radiotracer over all cortical regions, similar to that reported in normal subjects.9 The highest activity ratios were found in the occipital cortex, and the lowest in the superior frontal cortex. No significant differences in HM-PAO uptake ratios were found between NDPD and controls for any ofthe cortical regions (Scheff&'s test, p > 0-05). In contrast, mean tracer uptake was significantly reduced in the parietal, temporal and occipital cortex, but not in the superior and inferior frontal regions of DPD, compared with the NDPD group and controls (Scheff&'s test, p < 0-05). In the NDPD and DPD groups, regional perfusion bore no relation to the severity of the disease evaluated on the Hoehn and Yahr scale27 (ANOVA, p > 0-05).
In the DAT group, HM-PAO uptake ratios were significantly lower than those of controls Figure 2 In our study, the NDPD and DPD groups were well matched for age, disease duration, as well as for the amount and the duration of levodopa medication (table 1) . Most of the NDPD patients and only three of DPD were receiving DA agonist medication at the time of investigation. It is unlikely that DA agonists were responsible for the observed effects on cortical perfusion since it has been shown that they have similar effects to levodopa on rCBF. '7 A major difference between the NDPD and DPD groups was the presence of cortical atrophy (CA) in the DPD group: 13 out of 15 DPDs and only four out of 15 NDPDs had some evidence of mild and diffuse CA on CT scans. CA may bias regional measurement of rCBF and metabolism in ageing and dementia,' and may lead to spuriously low values of regional radioactivity uptake because of volume averaging between brain and non-brain (CSF) spaces. CA has, however, been shown to have a relatively small effect on regional brain metabolism or rCBF measured by PET,29 and focal metabolic abnormalities are only partially associated with regional CA changes.0 It should be noted that in our patients (NDPD and DPD), CA affected all cortical areas equally, and was not restricted to the posterior regions where alterations in perfusion were observed. It is therefore unlikely that atrophy alone can account for the observed differences in regional cerebral perfusion between the DPD and NDPD groups.
Relative to normal subjects, overall cortical perfusion was depressed in patients with DAT, with the largest reduction in the parietotemporal and superior frontal cortices, whereas occipital regions were relatively spared. These results agree with previous PET and SPECT studies reporting similar changes either in flow' or in brain metabolism.6 In contrast to previous reports,6 but in common with others,79 we did not find any significant positive correlation between the defects in regional perfusion and the severity of the cognitive impairment as evaluated by the MMS score. Our lack of significance, however, may have been due to the limited number of cases examined. Furthermore, the relative insensitivity of the MMS test should not be overlooked.3" Interestingly, the pattern of HM-PAO uptake reduction observed in DPD was similar to that found in DAT (fig 2) . In both groups, lesions were predominantly in the parietotemporal regions, although hypoperfusion was more severe in the DAT group. CT scans showed that the DPD and DAT patients had comparable diffuse CA. Single observations have indicated that DPD may be accompanied by a parieto-temporal hypometabolism that has been considered to be characteristic of DAT."
The nature of the dementia observed in PD is still controversial. The problem is to decide whether the dementia is due to coincidental DAT or to pathology specific to PD itself. The cognitive deficit in PD has generally been referred to as subcortical dementia,4 in contrast to cortical dementia such as that found in DAT, but the clinical and anatomical bases of this distinction are open to criticism. First, the neuropsychological features in the two conditions are not always clear-cut. 4 Second, several studies have provided evidence for an overlap of histological2632 and neurochemical"34 cortical and subcortical lesions underlying the dementia in both diseases. Taken together, these findings indicate that dementia in PD may be due to the coexistence of PD with DAT.'4 Cognitive impairment may be present in Parkinsonian patients with no evidence of DAT brain pathology. '5 In addition, DAT-like dementia may be associated with Parkinsonism in patients with widespread cortical Lewy bodies, but without the histological lesions that are characteristic of DAT. '6 In conclusion, our results demonstrate that dementia in PD, as defined by DSM-III-R criteria," is accompanied by marked defects in the perfusion of posterior cortical structures, which resemble the pattern of defects observed in DAT. Further neuropsychological and clinicopathological studies will be needed to clarify the relationship between these two disorders.
